Abstract：Objective: To investigate the short-term efficacy and adverse reactions of albumin-bound paclitaxel in the treatment of cervical squamous cell carcinoma.Methods: From October 2019 to October 2022, 124 patients with cervical squamous cell carcinoma treated at our hospital were selected as subjects and randomly divided into two groups (observation group with 62 cases and control group with 62 cases). Both groups received radiotherapy; the control group was treated with paclitaxel combined with cisplatin, while the observation group was given albumin-bound paclitaxel combined with cisplatin. Clinical efficacy and occurrence of toxic side effects during treatment were recorded after four cycles. Changes in serum tumor markers [squamous cell carcinoma antigen (SCCA), carcinoembryonic antigen (CEA), carbohydrate antigen (CA125)] and T lymphocyte levels (CD3+, CD4+, CD8+) before and after four cycles of treatment were compared between the two groups.Results: After four cycles of treatment, the observation group had a higher treatment efficacy rate (P<0.05). There was no statistically significant difference in the occurrence of toxic side effects between the two groups during treatment (P>0.05). Serum levels of SCCA, CEA, and CA125 decreased in both groups after four cycles of treatment, with a more significant decrease in the observation group (P<0.05). Serum levels of CD3+ and CD4+ decreased in both groups, with a more significant decrease in the control group, while CD8+ levels increased, with a more significant increase in the control group (P<0.05).Conclusion: Albumin-bound paclitaxel is significantly effective in treating cervical squamous cell carcinoma, can effectively control the progression of the disease, and has high safety, making it suitable for clinical promotion.
吴嘉纯, 朱莺, 邹美英, 武雅琴, 周超. 白蛋白结合型紫杉醇治疗宫颈鳞癌的近期疗效和不良反应分析[J]. 河北医学, 2024, 30(6): 1040-1044.
WU Jiachun, ZHU Ying, ZOU Meiying, et al. Analysis of the Short-Term Efficacy and Adverse Reactions of Albumin-Bound Paclitaxel in the Treatment of Cervical Squamous Cell Carcinoma. HeBei Med, 2024, 30(6): 1040-1044.
[1] 黄晓岚,魏文斐,陈晓静,等.CAFs联合LVD对早期宫颈鳞癌淋巴结转移的预测价值[J].现代妇产科进展,2023,32(4):241-247. [2] Zhang X,Zhang Q,Chen Y,et al.MRI-based radiomics for pretreatment prediction of response to concurrent chemoradiotherapy in locally advanced cervical squamous cell cancer.[J].Abdominal radiology (New York),2022,48(1):367-376. [3] 何惠兰,史惠蓉,贾艳艳.紫杉醇与顺铂新辅助化疗联合同步放化疗治疗局部晚期宫颈鳞状细胞癌患者的疗效观察[J].癌症进展,2019,17(17):2038-2040,2100. [4] 刘金玉,武小冬,陈孟莉.帕博利珠单抗联合白蛋白结合型紫杉醇及卡铂致严重视神经病变1例[J].医药导报,2023,42(5):764-766. [5] 谢幸,苟文丽.妇产科学[M].第8版.北京:人民卫生出版社,2013.64-71. [6] 路双,张宏凯,贾争艳,等.表观扩散系数值联合循环肿瘤细胞对食管鳞癌放化疗疗效的研究[J].实用放射学杂志,2020,36(7):1039-1042. [7] Ashley LM,Vaidehi A,Marina BM,et al.Programmed death ligand-1 expression is associated with poorer survival in anal squamous cell carcinoma[J].Archives of Pathology & Laboratory Medicine,2022,146(9):1094-1101. [8] Qin L.Study on the preoperative value of serum SCC-Ag in predicting the stromal invasion of cervical squamous cell carcinoma.[J].Journal of cancer research and clinical oncology,2023,23(5):36-42. [9] 邵佳,何爱琴,张璨,等.三种指标联合检测对中晚期宫颈鳞癌患者预后的预测价值[J].中华放射肿瘤学杂志,2022,31(10):904-909. [10] 王晓丹,宋国庆,姜丹.miR-28-5p通过抑制FSP1介导的铁死亡逆转肺腺癌细胞顺铂耐药的机制[J].安徽医科大学学报,2023,58(4):630-636. [11] 陆娟凤.多西紫杉醇+顺铂同步放化疗对中晚期子宫颈癌患者血清肿瘤标记物的影响和生存观察[J].中国妇幼保健,2021,36(13):3100-3103. [12] 张莹,王灿,刘俊伯.贝伐珠单抗联合白蛋白结合型紫杉醇加奈达铂治疗复发宫颈癌的效果观察[J].中国肿瘤临床与康复,2022,29(6):728-731. [13] 朱冰鸥,孙红霞,崔秀红.白蛋白结合型紫杉醇新辅助化疗治疗中晚期宫颈癌的疗效及对肿瘤负荷的影响[J].临床和实验医学杂志,2020,19(1):61-64.
2024, Vol. 30 
冀公网安备13080202000677号